Research & Literature

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.

Ramsey LB, Janke LJ, Payton MA, et al.

PloS one 2015; (10(8)):e0135134 doi:10.1371/journal.pone.0135134.

Acute Lymphoblastic Leukemia in Children.

Hunger SP, Mullighan CG

The New England journal of medicine 2015; (373(16)):1541-52 doi:10.1056/NEJMra1400972.

CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients.

Xu N, Li YL, Zhou X, et al.

Journal of Cancer 2015; (6(11)):1114-20 doi:10.7150/jca.11959.

The origin of relapse in pediatric T-cell acute lymphoblastic leukemia.

Vicente C, Cools J

Haematologica 2015; (100(11)):1373-5 doi:10.3324/haematol.2015.136077.

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.

Egler RA, Ahuja SP, Matloub Y

Journal of pharmacology & pharmacotherapeutics 2016; (7(2)):62-71 doi:10.4103/0976-500X.184769.

IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.

Ruiz-Delgado GJ, Cantero-Fortiz Y, León-Peña AA, et al.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2016; (68(4)):210-4.

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.

Issa GC, Kantarjian HM, Yin CC, et al.

Cancer 2017; (123(3)):459-467 doi:10.1002/cncr.30376.

Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America.

Jaime-Pérez JC, Jiménez-Castillo RA, Pinzón-Uresti MA, et al.

Pediatric blood & cancer 2017; (64(7)) doi:10.1002/pbc.26396.

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

Martinelli G, Boissel N, Chevallier P, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(16)):1795-1802 doi:10.1200/JCO.2016.69.3531.

Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.

Schmiegelow K, Müller K, Mogensen SS, et al.

F1000Research 2017; (6()):444 doi:10.12688/f1000research.10768.1.

A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

Keeney M, Wood BL, Hedley BD, et al.

Cytometry. Part B, Clinical cytometry 2018; (94(2)):239-249 doi:10.1002/cyto.b.21528.

TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.

Klaassen ILM, Lauw MN, van de Wetering MD, et al.

BMC pediatrics 2017; (17(1)):122 doi:10.1186/s12887-017-0877-x.

Managing CNS disease in adults with acute lymphoblastic leukemia.

Larson RA

Leukemia & lymphoma 2018; (59(1)):3-13 doi:10.1080/10428194.2017.1326597.

First case of B ALL with KMT2A-MAML2 rearrangement: a case report.

Menu E, Beaufils N, Usseglio F, et al.

BMC cancer 2017; (17(1)):363 doi:10.1186/s12885-017-3368-4.

Altered brain function in new onset childhood acute lymphoblastic leukemia before chemotherapy: A resting-state fMRI study.

Hu Z, Zou D, Mai H, et al.

Brain & development 2017; (39(9)):743-750 doi:10.1016/j.braindev.2017.04.014.

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach.

Keramatinia A, Ahadi A, Akbari ME, et al.

Journal of cancer prevention 2017; (22(2)):74-81 doi:10.15430/JCP.2017.22.2.74.

Immunological Subtypes of Acute Lymphoblastic Leukemia- Beyond Morphology: Experience from Kidwai State Cancer Institute, Bengaluru, India.

Rajkumar NN, Vijay RH

The Journal of the Association of Physicians of India 2017; (65(7)):14-17.

Metacognitive Therapy for Emotional Distress in Adult Cancer Survivors: A Case Series.

Fisher PL, Byrne A, Salmon P

Cognitive therapy and research 2017; (41(6)):891-901 doi:10.1007/s10608-017-9862-9.

[Research progress in Ph-like childhood acute lymphoblastic leukemia].

Tang X, Guo X

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2017; (19(11)):1213-1218.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

Kantarjian H, Ravandi F, Short NJ, et al.

The Lancet. Oncology 2018; (19(2)):240-248 doi:10.1016/S1470-2045(18)30011-1.

Behavioral symptoms and psychiatric disorders in child and adolescent long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.

Liu W, Cheung YT, Brinkman TM, et al.

Psycho-oncology 2018; (27(6)):1597-1607 doi:10.1002/pon.4699.

Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.

Siegel SE, Advani A, Seibel N, et al.

American journal of hematology 2018; (93(10)):1254-1266 doi:10.1002/ajh.25229.

IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.

Alsadeq A, Lenk L, Vadakumchery A, et al.

Blood 2018; (132(15)):1614-1617 doi:10.1182/blood-2018-04-844209.

A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings.

Parihar M, Singh MK, Islam R, et al.

Pediatric blood & cancer 2018; (65(12)):e27366 doi:10.1002/pbc.27366.

Lactic Acidosis in a Critically Ill Patient: Not Always Sepsis.

Schuh AM, Leger KJ, Summers C, Uspal NG

Pediatric emergency care 2018; (34(9)):e165-e167 doi:10.1097/PEC.0000000000001603.

The Impact of Persistent Leukoencephalopathy on Brain White Matter Microstructure in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.

Sabin ND, Cheung YT, Reddick WE, et al.

AJNR. American journal of neuroradiology 2018; (39(10)):1919-1925 doi:10.3174/ajnr.A5791.

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.

Jen EY, Xu Q, Schetter A, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(2)):473-477 doi:10.1158/1078-0432.CCR-18-2337.

Therapy-related acute lymphoblastic leukemia.

Ribera JM

Haematologica 2018; (103(10)):1581-1583 doi:10.3324/haematol.2018.200311.

Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.

Yeh TC, Liang DC, Hou JY, et al.

Cancer 2018; (124(23)):4538-4547 doi:10.1002/cncr.31758.

Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.

Chen J, Ngo D, Aldoss I, et al.

Leukemia & lymphoma 2019; (60(5)):1187-1192 doi:10.1080/10428194.2018.1519811.

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.

Angelova E, Audette C, Kovtun Y, et al.

Haematologica 2019; (104(4)):749-755 doi:10.3324/haematol.2018.205252.

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.

Short NJ, Jabbour E, Albitar M, et al.

American journal of hematology 2019; (94(2)):257-265 doi:10.1002/ajh.25338.

Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.

Schumich A, Maurer-Granofszky M, Attarbaschi A, et al.

Pediatric blood & cancer 2019; (66(5)):e27590 doi:10.1002/pbc.27590.

Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia.

Milosevic G, Kotur N, Krstovski N, et al.

Journal of medical biochemistry 2018; (37(3)):320-327 doi:10.1515/jomb-2017-0060.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Gu Z, Churchman ML, Roberts KG, et al.

Nature genetics 2019; (51(2)):296-307 doi:10.1038/s41588-018-0315-5.

Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.

El Chaer F, Holtzman NG, Sausville EA, et al.

Acta haematologica 2019; (141(2)):107-110 doi:10.1159/000495558.

Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis.

Finch ER, Janke LJ, Smith CA, et al.

Pediatric blood & cancer 2019; (66(6)):e27669 doi:10.1002/pbc.27669.

Brief Metacognitive Therapy for Emotional Distress in Adult Cancer Survivors.

Fisher PL, Byrne A, Fairburn L, et al.

Frontiers in psychology 2019; (10()):162 doi:10.3389/fpsyg.2019.00162.

Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia.

Shah G, Mikhail FM, Carroll AJ, et al.

Case reports in hematology 2019; (2019()):3536517 doi:10.1155/2019/3536517.

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.

Bassan R, Brüggemann M, Radcliffe HS, et al.

Haematologica 2019; (104(10)):2028-2039 doi:10.3324/haematol.2018.201053.

Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988-2012.

Hubbard AK, Spector LG, Fortuna G, et al.

JNCI cancer spectrum 2019; (3(1)):pkz007 doi:10.1093/jncics/pkz007.

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Stein AS, Kantarjian H, Gökbuget N, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(8)):1498-1504 doi:10.1016/j.bbmt.2019.04.010.

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.

Tanasi I, Ba I, Sirvent N, et al.

Blood 2019; (134(16)):1351-1355 doi:10.1182/blood.2019001244.

Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation.

Yang F, Yang X, Bao X, et al.

Leukemia & lymphoma 2020; (61(2)):429-436 doi:10.1080/10428194.2019.1663417.

Mechanisms by Which Obesity Impacts Survival from Acute Lymphoblastic Leukemia.

Orgel E, Sea JL, Mittelman SD

Journal of the National Cancer Institute. Monographs 2019; (2019(54)):152-156 doi:10.1093/jncimonographs/lgz020.

BCR-ABL1-like B-Acute Lymphoblastic Leukemia/Lymphoma: A Comprehensive Review.

Jain S, Abraham A

Archives of pathology & laboratory medicine 2020; (144(2)):150-155 doi:10.5858/arpa.2019-0194-RA.

Can Ph-like ALL be effectively targeted?

Maese L, Raetz EA

Best practice & research. Clinical haematology 2019; (32(4)):101096 doi:10.1016/j.beha.2019.101096.

Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL).

Stuckert AJ, Schafer ES, Bernhardt MB, et al.

Leukemia & lymphoma 2020; (61(5)):1246-1249 doi:10.1080/10428194.2019.1702183.

Brainstem auditory pathway of children with acute lymphoid leukemia on chemotherapy with methotrexate.

Leite RA, Vosgrau JS, Cortez Neto L, et al.

Arquivos de neuro-psiquiatria 2020; (78(2)):63-69 doi:10.1590/0004-282X20190139.

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.

Ribera JM, Morgades M, Montesinos P, et al.

Cancer medicine 2020; (9(7)):2317-2329 doi:10.1002/cam4.2814.

Acute lymphoblastic leukaemia.

Malard F, Mohty M

Lancet (London, England) 2020; (395(10230)):1146-1162 doi:10.1016/S0140-6736(19)33018-1.

Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).

Fuster JL, Molinos-Quintana A, Fuentes C, et al.

British journal of haematology 2020; (190(5)):764-771 doi:10.1111/bjh.16647.

Blastic Plasmacytoid Dendritic Cell Neoplasm in Children.

Li Y, Sun V, Sun W, Pawlowska A

Hematology/oncology clinics of North America 2020; (34(3)):601-612 doi:10.1016/j.hoc.2020.01.008.

Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.

Marchesini M, Gherli A, Montanaro A, et al.

Cell chemical biology 2020; (27(6)):678-697.e13 doi:10.1016/j.chembiol.2020.04.002.

A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia.

Capria S, Molica M, Mohamed S, et al.

Expert review of hematology 2020; (13(7)):755-769 doi:10.1080/17474086.2020.1770591.

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.

Chiaretti S, Messina M, Della Starza I, et al.

Haematologica 2021; (106(6)):1559-1568 doi:10.3324/haematol.2020.247973.

Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.

Salzer WL, Burke MJ, Devidas M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(23)):2628-2638 doi:10.1200/JCO.19.02892.

Who Should Receive an Allogeneic Transplant in First Complete Remission?

Ribera JM, Genescà E, Ribera J

Clinical lymphoma, myeloma & leukemia 2020; (20 Suppl 1()):S48-S51 doi:10.1016/S2152-2650(20)30459-6.

Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity.

Cohen G, Cooper S, Sison EA, et al.

Pediatric blood & cancer 2020; (67(11)):e28360 doi:10.1002/pbc.28360.

CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.

Leong S, Inglott S, Papaleonidopoulou F, et al.

Blood advances 2020; (4(19)):4665-4668 doi:10.1182/bloodadvances.2020002502.

Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.

Underwood B, Zhao Q, Walker AR, et al.

International journal of hematologic oncology 2020; (9(3)):IJH28 doi:10.2217/ijh-2020-0009.

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Couturier MA, Thomas X, Raffoux E, et al.

Leukemia & lymphoma 2021; (62(3)):620-629 doi:10.1080/10428194.2020.1844198.

Aberrant immunophenotypes in acute lymphoblastic leukemia.

Cuéllar-Mendoza ME, Chávez-Sánchez FR, Dorantes-Acosta E, et al.

Boletin medico del Hospital Infantil de Mexico 2020; (77(6)):287-292 doi:10.24875/BMHIM.20000171.

TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia.

Dreisig K, Brünner ED, Marquart HV, et al.

Pediatric hematology and oncology 2021; (38(3)):227-238 doi:10.1080/08880018.2020.1842570.

Pharmacogenomics and ALL treatment: How to optimize therapy.

Karol SE, Yang JJ

Seminars in hematology 2020; (57(3)):130-136 doi:10.1053/j.seminhematol.2020.10.001.

Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); KMT2A/EPS15, Following Blinatumomab Therapy.

Du J, Chisholm KM, Tsuchiya K, et al.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2021; (24(4)):378-382 doi:10.1177/10935266211001308.

Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.

Paietta E, Roberts KG, Wang V, et al.

Blood 2021; (138(11)):948-958 doi:10.1182/blood.2020010144.

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

Shah BD, Ghobadi A, Oluwole OO, et al.

Lancet (London, England) 2021; (398(10299)):491-502 doi:10.1016/S0140-6736(21)01222-8.

From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia.

Thakral B, Jain N, Tang G, et al.

Annals of diagnostic pathology 2021; (53()):151767 doi:10.1016/j.anndiagpath.2021.151767.

Hospital acquired pneumonia risk factors in children with Acute Lymphoblastic Leukemia on chemotherapy.

Mairuhu AM, Andarsini MR, Setyoningrum RA, et al.

Heliyon 2021; (7(6)):e07209 doi:10.1016/j.heliyon.2021.e07209.

Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.

Jeha S, Choi J, Roberts KG, et al.

Blood cancer discovery 2021; (2(4)):326-337 doi:10.1158/2643-3230.BCD-20-0229.

Why do subcutaneous ports get stuck? A case-control study.

Crook JL, Lu Z, Wang X, et al.

Journal of pediatric surgery 2022; (57(9)):229-233 doi:10.1016/j.jpedsurg.2021.08.003.

Long-term Follow-up Care for Childhood, Adolescent, and Young Adult Cancer Survivors.

Hudson MM, Bhatia S, Casillas J, et al.

Pediatrics 2021; (148(3)) doi:10.1542/peds.2021-053127.

Utilization of Thiopurine Metabolites and Allopurinol in Pediatric Acute Lymphoblastic Leukemia: Consideration for an Algorithmic Approach.

Mosher N, Torkildson J, Golden C, et al.

Journal of pediatric hematology/oncology 2022; (44(2)):e521-e525 doi:10.1097/MPH.0000000000002313.

Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.

Schulte R, Hinson A, Huynh V, et al.

Cancer medicine 2021; (10(21)):7551-7560 doi:10.1002/cam4.4281.

Acute pancreatitis in children with acute lymphoblastic leukemia correlates with L-asparaginase dose intensity.

Chen CB, Chang HH, Chou SW, et al.

Pediatric research 2022; (92(2)):459-465 doi:10.1038/s41390-021-01796-w.

BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.

Płotka A, Lewandowski K

Acta haematologica 2022; (145(2)):122-131 doi:10.1159/000519782.

Behavioral and Emotional Functioning of Children and Adolescents at the End of Treatment for Acute Lymphoblastic Leukemia Compared to Healthy Peers.

De Luca CR, Mulraney M, Anderson V, et al.

Journal of clinical psychology in medical settings 2022; (29(2)):421-431 doi:10.1007/s10880-021-09840-x.

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.

Hein K, Short N, Jabbour E, Yilmaz M

Blood and lymphatic cancer : targets and therapy 2022; (12()):7-16 doi:10.2147/BLCTT.S270134.

MYC degradation via AURKB inhibition: a new brake in the path to T-ALL.

Zhang W, Pear WS

Blood science (Baltimore, Md.) 2020; (2(2)):68-69 doi:10.1097/BS9.0000000000000046.

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.

Saleh K, Fernandez A, Pasquier F

Cancers 2022; (14(7)) doi:10.3390/cancers14071805.

Risk Stratification and Cancer Follow-Up: Towards More Personalized Post-Treatment Care in Canada.

Urquhart R, Cordoba W, Bender J, et al.

Current oncology (Toronto, Ont.) 2022; (29(5)):3215-3223 doi:10.3390/curroncol29050261.

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience.

Ibrahim RI, Saeed AM

Asian Pacific journal of cancer prevention : APJCP 2022; (23(5)):1647-1651 doi:10.31557/APJCP.2022.23.5.1647.

A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen.

Watson C, Gadikota H, Barlev A, Beckerman R

Journal of drug assessment 2022; (11(1)):1-11 doi:10.1080/21556660.2022.2073101.

Bacteriological Spectrum and Antibiotic Susceptibility on Blood Culture in Newly Diagnosed Pediatric Patients With Acute Lymphoblastic Leukemia During the Induction Phase.

Fawad U

Cureus 2022; (14(5)):e25470 doi:10.7759/cureus.25470.

Sequential Approach to Improve the Molecular Classification of Childhood Acute Lymphoblastic Leukemia.

Yu CH, Wu G, Chang CC, et al.

The Journal of molecular diagnostics : JMD 2022; (24(11)):1195-1206 doi:10.1016/j.jmoldx.2022.08.001.

Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.

Zak T, Gao J, Behdad A, et al.

Leukemia & lymphoma 2022; (63(13)):3200-3207 doi:10.1080/10428194.2022.2113524.

Recent research on the association between signal transducer and activator of transcription 5 and childhood acute lymphoblastic leukemia.

Duan YF, Wen FQ

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2022; (24(8)):942-947 doi:10.7499/j.issn.1008-8830.2203117.

SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL.

Aldoss I, Pourhassan H, Douer D

Clinical lymphoma, myeloma & leukemia 2022; (22(11)):787-794 doi:10.1016/j.clml.2022.08.009.

Go with the Flow-Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009.

Pawinska-Wasikowska K, Bukowska-Strakova K, Surman M, et al.

Cancers 2022; (14(21)) doi:10.3390/cancers14215359.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

Jabbour E, Short NJ, Jain N, et al.

The Lancet. Haematology 2023; (10(1)):e24-e34 doi:10.1016/S2352-3026(22)00319-2.

Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.

Shahzad M, Hussain A, Tariq E, et al.

Clinical lymphoma, myeloma & leukemia 2023; (23(3)):178-187 doi:10.1016/j.clml.2023.01.002.

Safety of re-challenging adults with acute lymphoblastic leukemia with PEG-asparaginase-induced severe hypertriglyceridemia when treated with a pediatric-inspired regimen.

Al Nabhani I, Andrews C, Sibai J, et al.

EJHaem 2023; (4(1)):232-235 doi:10.1002/jha2.607.

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.

Ribera JM, Prawitz T, Freitag A, et al.

Advances in therapy 2023; (40(7)):3087-3103 doi:10.1007/s12325-023-02497-y.

Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization.

L'Abbate A, Moretti V, Pungolino E, et al.

Genes 2023; (14(7)) doi:10.3390/genes14071351.

Impact of Mercaptopurine Metabolites on Disease Outcome in the AIEOP-BFM ALL 2009 Protocol for Acute Lymphoblastic Leukemia.

Franca R, Stocco G, Kiren V, et al.

Clinical pharmacology and therapeutics 2023; (114(5)):1082-1092 doi:10.1002/cpt.3022.

Acute lymphoblastic leukemia in young adults: which up-front treatment?.

Molina JC, Rotz S

Hematology. American Society of Hematology. Education Program 2023; (2023(1)):573-580 doi:10.1182/hematology.2023000510.

Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.

Foà R, Bassan R, Elia L, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(8)):881-885 doi:10.1200/JCO.23.01075.

SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia.

Senapati J, Kantarjian H, Haddad FG, et al.

Clinical lymphoma, myeloma & leukemia 2024; (24(6)):333-339 doi:10.1016/j.clml.2023.12.013.

Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes.

Choi JK, Xiao W, Chen X, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2024; (37(5)):100466 doi:10.1016/j.modpat.2024.100466.

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.

Ribera JM, Morgades M, Ribera J, et al.

HemaSphere 2024; (8(4)):e67 doi:10.1002/hem3.67.

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine.

Hu M, Li W, Li P, et al.

Frontiers in oncology 2024; (14()):1329279 doi:10.3389/fonc.2024.1329279.

Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?

Sohn SK, Lee JM, Jang Y, et al.

Expert review of hematology 2024; (17(7)):353-359 doi:10.1080/17474086.2024.2357273.

Long-Term Remission in T315I+ Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Blinatumomab and Allogeneic Stem Cell Transplantation: Two Case Studies.

Huang Z, Zhang Y, Chen J, et al.

The American journal of case reports 2024; (25()):e944956 doi:10.12659/AJCR.944956.

Hyper-CVAD and Modified CALGB-10403 Regimens in Adult Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: A Comparative Study.

Zalapa-Soto J, Rios-Olais FA, Chacón-Rangel LC, et al.

European journal of haematology 2025; (114(5)):793-801 doi:10.1111/ejh.14381.

The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review.

DeVine A, Landier W, Hudson MM, et al.

JAMA oncology 2025; (11(5)):544-553 doi:10.1001/jamaoncol.2024.6812.

Complications during central venous access device removal in children: A systematic review and meta-analysis.

Sakthivel M, Sakthivel D, Nataraja RM, Pacilli M

Journal of pediatric surgery 2025; 162445 doi:10.1016/j.jpedsurg.2025.162445.

Life is an ongoing existential battle - experiences from adult survivors after allogeneic hematopoietic stem cell transplantation during childhood acute lymphoblastic leukemia.

Olsson M, Aili K, Jarfelt M, et al.

European journal of oncology nursing : the official journal of European Oncology Nursing Society 2025; (77()):102929 doi:10.1016/j.ejon.2025.102929.

Multiple Lineage Switches in a Pediatric Case With a KMT2A::AFF1-Positive Acute Lymphoblastic Leukemia: How Cell Plasticity Induces Immunotherapy Failure.

Lo Nigro L, Arrabito M, Cannata E, et al.

Pediatric blood & cancer 2025; (72(10)):e31950 doi:10.1002/pbc.31950.

DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.

Bakewell J, Moorman AV, Ryan SL

Leukemia 2025; (39(12)):2835-2847 doi:10.1038/s41375-025-02758-5.

Characterizing Parental Concerns About Lasting Impacts of Treatment in Children With B-Acute Lymphoblastic Leukemia.

Parker KN, Alexander SW, Jacola LM, et al.

Pediatric blood & cancer 2026; (73(4)):e70156 doi:10.1002/1545-5017.70156.